MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit for securities fraud, alleging that the company made false and misleading statements regarding its drug candidate, sonelokimab (SLK), which led to significant losses for investors [4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against MoonLake Immunotherapeutics for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased securities between March 10, 2024, and September 29, 2025, are encouraged to contact the firm before December 15, 2025 [2]. - The lawsuit claims that MoonLake misled the market about the superiority of SLK over other monoclonal antibodies, despite lacking proven advantages [4]. Group 2: Impact on Investors - Following the announcement of a Phase 3 trial result deemed "disastrous" by analysts, MoonLake's shares lost almost 90% of their value [4]. - The company's public statements were characterized as false and materially misleading throughout the class period, resulting in damages for investors when the truth was revealed [4].